阿托伐他汀对高血压合并高低密度脂蛋白胆固醇血症患者肾功能的影响价值分析

Analysis of effect value of atorvastatin on renal function in patients with hypertension complicated with high and low density lipoprotein cholesterolemia

目的观察分析阿托伐他汀对高血压合并高低密度脂蛋白胆固醇血症患者肾功能的影响。方法 86例高血压合并高低密度脂蛋白胆固醇血症患者,依照入院顺序将其分成对照组和观察组,每组43例。对照组患者采用苯磺酸氨氯地平治疗,观察组患者在对照组治疗基础上加用阿托伐他汀治疗。比较两组患者的治疗效果。结果治疗前,两组患者血压、肾小球滤过率及血肌酐水平比较差异无统计学意义(P>0.05);治疗后,观察组患者血压、肾小球滤过率及血肌酐水平均优于对照组,差异具有统计学意义(P<0.05)。治疗后,观察组患者高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、尿微量白蛋白水平分别为(1.4±0.5)mmol/L、(2.8±0.5)mmol/L、(65.2±6.4)mg/L,均优于对照组的(1.0±0.2)mmol/L、(3.2±0.9)mmol/L、(77.8±8.2)mg/L,差异具有统计学意义(P<0.05)。两组患者治疗期间不良反应发生率比较差异无统计学意义(X^2=0.2123, P>0.05)。结论针对高血压合并高低密度脂蛋白胆固醇血症患者采用阿托伐他汀配合苯磺酸氨氯地平治疗,安全性较高,可有效提高临床治疗效果,改善患者临床各项指标水平。

Objective To observe and analyze the effect of atorvastatin on renal function in patients with hypertension complicated with high and low density lipoprotein cholesterolemia. Methods A total of 86 patients with hypertension complicated with high level of low density lipoprotein cholesterolemia were divided by admission order into control group and observation group, with 43 cases in each group. The control group was treated with amlodipine besylate, and the observation group was treated with atorvastation on the basis of the control group. The treatment effect of the two groups was compared. Results Before treatment, both groups had no statistically significant difference in blood pressure, glomerular filtration rate and serum creatinine level (P>0.05). After treatment, the observation group had better lood pressure, glomerular filtration rate and serum creatinine level than the control group, and the difference was statistically significant (P<0.05). After treatment, the observation group had high density lipoprotein cholesterol, low density lipoprotein cholesterol and urinary microalbumin levels respectively as (1.4±0.5) mmol/L,(2.8±0.5) mmol/L and (65.2±6.4) mg/L than (1.0±0.2) mmol/L,(3.2± 0.9) mmol/L and (77.8±8.2) mg/L in the control group, and their difference was statistically significant (P<0.05). Both groups had no statistically significant in incidence of adverse reactions during treatment (χ^2=0.2123, P>0.05). Conclusion Combination of atorvastatin and amlodipine besylate can effectively improve the clinical treatment effect and improve the clinical indexes levels of patients with high and low density lipoprotein cholesterolemia with high safety.